1367 – Gastrointestinal liner ['EndoBarrier'] to treat diabetes and obesity

New MBS item.

EndoBarrier is a duo-denal jejunal bypass sleeve that achieves the metabolic effects of a surgical gastric bypass, with reduced risk. The EndoBarrier prevents nutrient contact with the proximal intestinal mucosa. Bile and pancreatic secretions pass along the outer wall of the impermeable 60cm liner and mix with the chime as it exits distal to the inner in the jejunum. By creating a physical barrier to food absorption, EndoBarrier reduces the uptake of nutrients from the first part of the small bowel and may also have an effect on key metabolic hormones, including intretin. As a result, patients using EndoBarrier may experience substantial clinical benefits in terms of weight loss and glycemic status.

Type: Therapeutic

Type 2 diabetes is a metabolic disorder that is characterised by high blood glucose in the context of insulin resistance and relative insulin deficiency. Long-term complications from high blood sugar can include heart disease, strokes, diabetic retinopathy where eyesight is affected, kidney failure which may require dialysis and poor circulation of limbs leading to amputations. If lifestyle interventions are not successful, patients with type 2 diabetes are generally advised to take oral blood glucose lowering drugs.

Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy, and / or increased health problems. Obesity increases the likelihood of various diseases, particularly heart disease, type 2 diabetes, obstructive sleep apnea, certain types of cancer, and osteoarthritis. Clinically severe obesity is a condition generally defined as BMI over 40 or between 35 and 40 where there are other major medical conditions such as high blood pressure and diabetes.

• PASC meeting: 12 - 13 December 2013
• ESC meeting: 8 - 10 October 2014
• MSAC meeting: -